6JH Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
IN8bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$0.29 |
| 52 Week Low | US$0.27 |
| Beta | 0.025 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6JH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | -0.5% |
| 1Y | n/a | -5.8% | 15.5% |
Return vs Industry: Insufficient data to determine how 6JH performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6JH performed against the German Market.
Price Volatility
| 6JH volatility | |
|---|---|
| 6JH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 6JH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6JH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 18 | William Ho | in8bio.com |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
IN8bio, Inc. Fundamentals Summary
| 6JH fundamental statistics | |
|---|---|
| Market cap | €15.01m |
| Earnings (TTM) | -€27.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 6JH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6JH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.44m |
| Earnings | -US$30.44m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6JH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/15 04:07 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IN8bio, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |